Portland, OR -- (SBWIRE) -- 09/26/2017 -- Retinoic acid is a metabolite of vitamin A (retinol) that mediates the functions of vitamin A required for growth and development. It is a member of family of retinoids, that are compound either derived from vitamin A or are structurally similar to it.
Access the full summary at: https://www.alliedmarketresearch.com/retinoic-acid-market
Rise in incidences of cancers as retinoids find an important application in cancer therapeutics drive the market. In addition, retinoic acid is widely used for the treatment of photoaged skin, psoriasis, skin lesions of Kaposis sarcoma, and for cancers of breast and prostate also fuel the market growth. However, isotretinoin; a form of retinoic acid; is highly teratogenic.
As teratogenic drug can disturb the development of an embryo, therefore the use of retinoic acid is strictly controlled. This restrains the market growth. Conversely, increase in research for the cure of cancers and advancements in cancer therapeutics provide ample opportunities for the market growth.
Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/4051
The key players operating in the market include LGM Pharma, GF Health Products, Inc., GYMA Laboratories of America, Inc., Genemed Synthesis Inc., IMCoPharma a. s., Chongqing Huabang Pharmacy Co., Ltd., Olon S.p.A., and Sun Pharmaceutical Industries Ltd.
Retinoic Acid Market Key Segments:
By Mode of Administration
-Oral
-External
By End User
-Hospital Pharmacy
-Online Pharmacy
-Retail Pharmacy
Early buyers will receive 20% customization on this report